Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection
Status:
Unknown status
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
MyoCell™ implantation by epicardial injection during CABG surgery has the potential to add a
new dimension to the management of post-infarct deterioration of cardiac function. Based on
existing non-clinical studies and clinical reports, implantation of autologous skeletal
myoblasts appears to lead to the replacement of non-functioning myocardial scar with
functioning muscle and appears to improve myocardial performance relative to case without
myoblast implantation. In a few investigational patients, myoblast implantation can be, and
has been, done in conjunction with CABG and appears to have the potential to provide for
additive treatment during surgery. The present study is being conducted to evaluate more
fully the safety of MyoCell™ implantation via epicardial injection during CABG surgery and
its effect on regional myocardial function.